evipedia.ai
← Back

Butea superba to Improve Testosterone

Evidence Review created on 09/14/2026 using AI4L / Opus 5

Also known as: Red Kwao Krua, Red Kwao Khruea, Kwao Khruea Daeng, Butea superba Roxb.

Motivation

Butea superba, known in Thailand as Red Kwao Krua, is a climbing legume whose thick tuberous root has been taken by Thai men for generations as a vitality tonic. It now sells worldwide as an oral supplement promoted to raise testosterone, sharpen sex drive and firm erections. The root is rich in a family of plant compounds also found in soy and red clover, and sellers describe these as plant-made male hormones that act much like the body’s own.

The herb belongs to a Thai folk group of root medicines sorted by colour — white for women, red for men, black for both. Red Kwao Krua reached Western shelves in the early 2000s on the strength of Thai laboratory work and one small trial in men with erection difficulties, and it now appears mostly as one ingredient inside blended male-vitality products.

This review examines what is actually established about Butea superba and testosterone: what the root contains, what it did in animals and in men, where the human record stops, and which safety and product-quality questions remain open.

Benefits - Risks - Protocol - Conclusion

A short list of high-level sources that discuss Butea superba and the wider class of botanical male-potency agents in depth.

None of the six priority platforms yields usable material. Web and on-site searches of foundmyfitness.com, peterattiamd.com, hubermanlab.com, chriskresser.com, lifeextension.com and lifespan.io returned no article, episode or commentary that names Butea superba; their male-hormone coverage centres on testosterone replacement and on better-studied botanicals such as ashwagandha and tongkat ali.

Grokipedia

Butea superba

Covers the plant’s botany, phytochemistry and traditional Thai use, then separates preclinical from human trial evidence and closes with a toxicity and contraindication section, giving a single broad orientation to the root.

Examine

Butea superba

Grades the evidence as weak, notes that both erection trials are flawed, and flags the paradoxical fall in serum testosterone alongside androgen-like tissue effects.

ConsumerLab

No ConsumerLab article, product review or clinical update dedicated to Butea superba exists. The site’s sexual-enhancement coverage tests yohimbe, horny goat weed and arginine products, not Red Kwao Krua.

Systematic Reviews

Systematic reviews and meta-analyses covering Butea superba directly, and the broader evidence on botanical testosterone and erectile agents in which it is assessed.

The claimed effect is represented above. The principal risk is not: no systematic review or meta-analysis addresses androgen-axis suppression by Butea superba, nor the undeclared-drug adulteration of Red Kwao Krua products, and that side of the trade-off is therefore unrepresented in the systematic-review literature.

Mechanism of Action

The tuberous root carries isoflavones and related flavonoids — daidzein, genistein, biochanin A, formononetin, prunetin and medicarpin — together with plant sterols such as β-sitosterol, campesterol and stigmasterol (Ngamrojanavanich et al., 2007; Sirichaiwetchakoon & Eumkeb, 2024).

Two competing accounts are offered for its reputation, and they predict opposite hormonal results.

The phytoandrogen account holds that these compounds act on the androgen receptor (the protein that male hormones switch on inside cells). Rodent work supports part of it: accessory sex organs enlarge while circulating testosterone falls at high doses — the signature of an outside androgen damping the body’s own output through negative feedback on the hypothalamic-pituitary-testicular axis (the hormone loop running from brain to testes) (Cherdshewasart et al., 2008; Malaivijitnond et al., 2010).

The vascular account needs no hormone at all: extracts relax the smooth muscle of erectile tissue and amplify cyclic guanosine monophosphate (the signalling molecule that keeps that tissue relaxed), behaving like a weak phosphodiesterase inhibitor (a drug class that stops that molecule from being broken down) (Tocharus et al., 2006). The same extract also binds estrogen receptors in yeast screens, more strongly at the beta receptor than the alpha (Cherdshewasart et al., 2010).

No human pharmacokinetic study of the extract exists. Its marker isoflavones are absorbed as glucuronides with a half-life near seven to nine hours, and are handled mainly by UGT enzymes (which attach glucuronide tags for excretion).

Historical Context & Evolution

Kwao Krua is a Thai folk category rather than one plant: white (Pueraria candollei) for women, red (Butea superba) for men, black (Mucuna species) for both. Traditional Thai texts describe the red root as a rejuvenating agent for ageing men, macerated in liquor or dried and powdered, taken to restore strength, stamina and sexual capacity.

The original intended use was never hormone elevation as such — it was restoration of male potency. The hormonal framing arrived later, applied by Western supplement marketing that recast the root as a natural testosterone booster.

Interest moved from folklore to laboratory in the 1990s, when Thai plant-medicine research groups, principally Wichai Cherdshewasart’s at Chulalongkorn University, began profiling the flavonoids and feeding the powder to rodents. What that research actually found is more mixed than either framing suggests: accessory sex organs grew, serum testosterone did not rise and sometimes fell, and luteinising hormone (the pituitary signal that tells the testes to make testosterone) dropped after castration (Malaivijitnond et al., 2010).

A 2010 open-label comparison against sildenafil appeared to confirm efficacy until the responding batch proved to contain an undeclared erection drug, confirmed by the natural-health-products company that supplied it and that had a direct commercial stake in the outcome (Cortés-González et al., 2010). That episode changed how later readers weigh the earlier positive reports without erasing them; the 2003 trial’s questionnaire findings still stand on their own terms, unreplicated.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no human clinical endpoint or validated clinical surrogate has been shown in more than one trial, because only two human studies of this root exist and the second was confounded by an adulterated product.

Medium 🟩 🟩

No benefit reaches Medium: no single adequately controlled human trial reports a between-group result on a validated scale or a hormone endpoint — the one randomised trial reported within-group change only, and no human study has measured testosterone at all.

Low 🟩

Erectile Function in Men with Erectile Dysfunction ⚠️ Conflicted

Root powder improved erectile scores in a three-month randomised trial, plausibly via blood flow rather than hormones (Cherdshewasart & Nimsakul, 2003). A later comparison found benefit only from a batch containing an undeclared erection drug (Cortés-González et al., 2010). Net reading: unadulterated root has not outperformed placebo.

Magnitude: In the randomised trial, 82.4% of treated men reported noticeable improvement and 4 of 5 items on the IIEF-5 (International Index of Erectile Function, a five-question erection questionnaire) improved within the group; the blinded arm of the 2010 comparison recorded no effect at 100 mg.

Sexual Desire and Subjective Drive

Increased drive is the most consistent user-reported effect and the presenting complaint in the only published human case of androgen excess from the root (Chaiyasit & Wiwnaitkit, 2012). Sexual-record improvement was also noted in the randomised trial. Both sources are uncontrolled, so expectancy cannot be separated from drug effect.

Magnitude: Direction is toward increased drive at intakes around 1 g of root powder daily, and it reversed within one week of stopping in the reported case; the literature reports no outcome figure, because no trial has applied a validated desire scale to this plant.

Speculative 🟨

Serum Testosterone ⚠️ Conflicted

Two-week rat dosing at 200 mg/kg raised serum testosterone (Sirichaiwetchakoon et al., 2021); ninety-day dosing lowered it (Cherdshewasart et al., 2008). No human study has measured it. Net reading: direction in humans is unknown.

Sperm Count and Motility

Isolated daidzein and genistein raised sperm number, motility and testosterone in mice (Eumkeb et al., 2017). Rat feeding raised sperm count 16% at a high dose (Manosroi et al., 2006). No human semen data exist.

Antioxidant Capacity and Resistance of Low-Density Lipoprotein to Oxidation ⭕️ Not Central to Improve Testosterone

Extract scavenged free radicals and protected isolated human low-density lipoprotein from oxidation in test tubes (Sirichaiwetchakoon & Eumkeb, 2024). This bears on cardiovascular risk, not androgen status; the basis is in-vitro assay only.

Memory and Mood ⭕️ Not Central to Improve Testosterone

Extract reversed memory loss in aged rats (Sirichaiwetchakoon et al., 2021) and acted like an antidepressant in stressed mice (Mizuki et al., 2014). This bears on cognition and mood, not androgen status. Animal work only.

Benefit-Modifying Factors

  • Equol-producer status: Only about a third of people carry gut bacteria that convert daidzein into equol (a far more potent androgen-receptor-blocking and estrogen-receptor-binding metabolite). Producers and non-producers may experience opposite hormonal effects from the same dose.

  • UGT1A1 and CYP19A1 variation: UGT1A1 (an enzyme that tags compounds for excretion) governs isoflavone clearance, and CYP19A1 encodes aromatase (the enzyme converting testosterone to estrogen). Slow-clearance and low-aromatase variants both raise effective exposure.

  • Baseline testosterone and sex hormone-binding globulin: Men already in the upper reference range have little headroom; isoflavones can raise sex hormone-binding globulin (the carrier protein that holds testosterone inactive), so total testosterone may move without free testosterone following.

  • Sex-based differences: In female rats the root thickened the uterus and lengthened the non-fertile phase of the cycle, an androgen-like action (Malaivijitnond et al., 2009). Human female data are absent, and the traditional use is male-only.

  • Pre-existing conditions: Erectile benefit in rodents was preserved in diabetes-induced erectile failure (Tocharus et al., 2012), suggesting the vascular route may still operate where hormone-driven routes fail.

  • Age-related considerations: Traditional and trial use targets men aged 30 to 70. Older men with age-related decline in testosterone have the most room to move, but also the most prostate and blood-count risk from any androgenic push.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse event has been documented in more than one human trial, because the randomised trial reported unchanged haematology and blood chemistry and the 2010 comparison published no adverse-event data at all.

Medium 🟥 🟥

Undeclared Phosphodiesterase-5 Inhibitors in Commercial Products

Products sold as Butea superba have been found blended with unlabelled erection drugs. In the sildenafil comparison, the batch that outperformed the drug was later confirmed by its own supplier to contain a phosphodiesterase-5 inhibitor — a drug class, including sildenafil and tadalafil, that relaxes blood vessels (Cortés-González et al., 2010). Consequences are severe hypotension with nitrates, and unmonitored dosing in men with heart disease.

Magnitude: The batch used in the open-label first part of the 2010 study was adulterated, and regulators have repeatedly recalled sexual-enhancement supplements for undeclared prescription drugs; ConsumerLab logged four such Amazon recalls in November 2024 alone.

Low 🟥

Androgen Excess with Raised Dihydrotestosterone

A healthy 35-year-old Thai man taking commercial capsules for hair loss developed a surge in sex drive and markedly raised dihydrotestosterone (the potent androgen made from testosterone in skin, scalp and prostate) (Chaiyasit & Wiwnaitkit, 2012). It resolved fully on stopping. Single uncontrolled case.

Magnitude: Dihydrotestosterone reached 1512 pg/mL against a reference range of 250–990 pg/mL, and returned to normal within one week of discontinuation.

Species Substitution and Unpredictable Potency

Market crude drugs sold as Kwao Khruea are frequently the wrong species, and a sample sold as the female herb Pueraria candollei proved on DNA barcoding to be Butea superba (Urumarudappa et al., 2022; Wiriyakarun et al., 2013). The consequence is unintended androgenic or estrogenic exposure.

Magnitude: Two of twenty Thai market and regulator-supplied samples were misidentified on barcoding, and misidentification of commercial Kwao Khruea drugs was described as persistent across eight tested market products.

Speculative 🟨

Suppression of Endogenous Testosterone ⚠️ Conflicted

Ninety days at 150–200 mg/kg lowered rat testosterone dose-dependently without lowering luteinising hormone (Cherdshewasart et al., 2008); shorter dosing raised it. Net reading: prolonged high intake plausibly suppresses, unproven in humans.

Growth of Androgen-Sensitive Tissue

Seminal vesicle weight rose in intact rats at 250 mg/kg and testis weight at 1250 mg/kg (Malaivijitnond et al., 2010; Manosroi et al., 2006). Whether prostate tissue responds similarly in men is untested.

Chromosome Damage at High Doses

Extract was non-mutagenic in bacterial assays but induced micronuclei (fragments of damaged chromosome) in rodent red cells at 300 mg/kg and above (Cherdshewasart et al., 2010; Pongpanparadon et al., 2002). Rodent data only.

Liver-Enzyme and Blood-Count Changes at High Doses

Rats at 150 mg/kg for ninety days showed raised alkaline phosphatase and aspartate aminotransferase (both liver enzymes), plus spleen enlargement. At 200 mg/kg the white-cell profile shifted (Cherdshewasart et al., 2008). Rodent data only.

Estrogen-Receptor Activation

Six compounds isolated from the wild tuber reached up to 15.5% of estradiol’s potency in human estrogen-receptor yeast screens, and liver metabolism raised extract potency further (Cherdshewasart et al., 2010). In-vitro only.

Risk-Modifying Factors

  • Equol-producer status: Gut conversion of daidzein to equol changes the hormonal signature of the same capsule. Equol binds the estrogen beta receptor strongly and also binds dihydrotestosterone, so producers may face a different balance of androgenic and estrogenic effects.

  • Baseline prostate-specific antigen and dihydrotestosterone: Men starting with prostate-specific antigen (a protein released by prostate tissue) above 2.5 ng/mL, or dihydrotestosterone in the upper reference band, have the least margin before an androgenic push produces urinary symptoms.

  • Sex-based differences: Androgenic effects on the uterus and cycle were shown in female rats (Malaivijitnond et al., 2009). Women, and anyone pregnant or breastfeeding, face masculinising and fetal-exposure risks that men do not.

  • Pre-existing health conditions: Prostate cancer, benign prostatic enlargement, polycythaemia (too many red blood cells), active liver disease and any nitrate-treated coronary disease each convert a mild androgenic or vasodilatory signal into a clinically meaningful hazard.

  • Genetic polymorphisms in UGT1A1 and SRD5A2: Reduced-function UGT1A1 slows isoflavone clearance and raises exposure. SRD5A2 encodes 5-alpha reductase (the enzyme making dihydrotestosterone); high-activity variants amplify scalp and prostate androgen effects.

  • Age-related considerations: Men over 60 combine falling drug clearance with rising baseline prostate volume and haematocrit (the red-cell share of blood), so the same intake carries more urinary, clotting and liver-enzyme risk than in men in their thirties.

Key Interactions & Contraindications

  • Nitrates and nitric-oxide donors (nitroglycerin, isosorbide mononitrate, amyl nitrite): Absolute contraindication where the product may be adulterated with a phosphodiesterase-5 inhibitor; the combination causes life-threatening hypotension. Mitigation is avoidance, not dose separation.

  • Phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil): Caution. The root itself amplifies cyclic guanosine monophosphate signalling, so co-use risks additive hypotension, flushing and headache. Mitigation is separating use by at least 24 hours and starting the drug at its lowest dose.

  • Alpha-blockers and antihypertensives (tamsulosin, doxazosin, amlodipine): Caution. Additive vasodilation can produce dizziness on standing. Mitigation is dosing at different times of day and monitoring blood pressure sitting and standing for the first two weeks.

  • Anticoagulants and antiplatelets (warfarin, apixaban, clopidogrel): Monitor. Isoflavones inhibit platelet aggregation and compete for hepatic metabolism, raising bleeding risk. Mitigation is checking the international normalised ratio (a clotting-time ratio) within two weeks of starting.

  • 5-alpha reductase inhibitors and anti-androgens (finasteride, dutasteride, bicalutamide): Caution. Androgen-receptor activity from the root directly opposes the therapeutic aim, potentially undoing prostate or hair-loss treatment. Mitigation is avoiding concurrent use.

  • Over-the-counter yohimbine and sympathomimetic decongestants (pseudoephedrine, phenylephrine): Caution. Both raise blood pressure and heart rate while the root lowers vascular tone, giving unpredictable swings. Mitigation is avoiding combined sexual-enhancement stack products.

  • Over-the-counter analgesics (aspirin, ibuprofen, naproxen): Monitor. Added antiplatelet effect increases bruising and gastrointestinal bleeding risk. Mitigation is limiting regular concurrent use and reporting unusual bruising.

  • Supplements with additive androgenic or pro-erectile effects (tongkat ali, Fadogia agrestis, tribulus, horny goat weed, DHEA (dehydroepiandrosterone, an adrenal hormone precursor), boron): Caution. Stacking multiplies androgenic load and haematocrit rise without multiplying evidence. Mitigation is using one agent at a time.

  • Supplements with additive vasodilatory effects (L-Citrulline, L-Arginine, pycnogenol, beetroot nitrate): Caution. Additive blood-pressure lowering can cause light-headedness. Mitigation is separating doses by several hours and monitoring standing blood pressure.

  • Supplements affecting the same clearance enzymes (soy isoflavones, red clover, grapefruit juice, St John’s wort): Monitor. Competing for UGT and CYP3A4 (a liver drug-processing enzyme) alters exposure in either direction. Mitigation is avoiding duplicate isoflavone sources.

  • Other interventions — testosterone replacement therapy: Caution. Adding a putative plant androgen to above-normal androgen provides no additional benefit and compounds haematocrit and prostate effects. Mitigation is choosing one approach and monitoring haematocrit quarterly.

Populations who should avoid Butea superba:

  • Men with diagnosed or suspected prostate cancer, or prostate-specific antigen above 4 ng/mL, or a free-to-total prostate-specific antigen ratio at or below 0.15
  • Men with benign prostatic enlargement causing an International Prostate Symptom Score above 19 (severe symptoms) or urinary retention
  • Anyone taking nitrates in any form, or with unstable angina or myocardial infarction (heart attack) within 90 days
  • Men with polycythaemia, defined as haematocrit above 52%
  • Anyone with active liver disease or liver enzymes above three times the upper limit of normal
  • Women who are pregnant, breastfeeding, or planning conception, and anyone with a hormone-sensitive cancer such as breast or endometrial cancer
  • Anyone under 18, in whom androgenic exposure may affect growth-plate closure and pubertal timing

Risk Mitigation Strategies

  • Third-party assay for undeclared drugs: Choosing products tested by an independent laboratory for phosphodiesterase-5 inhibitors and their analogues directly addresses the adulteration risk that invalidated the 2010 comparison and drives recurring regulatory recalls.

  • Botanical authentication before purchase: Requiring a certificate of analysis naming Butea superba confirmed by DNA barcoding mitigates species substitution, the documented failure in which Kwao Khruea market drugs proved to be the wrong plant entirely.

  • Conservative dosing at or below traditional intake: Keeping total daily root powder at 100–250 mg, rather than the 1000 mg used in the 2003 trial, holds exposure far below the 300 mg/kg rodent threshold associated with micronucleus formation.

  • Fixed eight-week ceiling with washout: Limiting continuous use to eight weeks followed by four weeks off mitigates the negative-feedback suppression of endogenous testosterone seen only in ninety-day rodent dosing, not in two-week dosing.

  • Baseline and eight-week hormone panel: Measuring total and free testosterone, luteinising hormone and dihydrotestosterone before and after a course detects both the androgen excess reported in the human case and any suppression of the body’s own production.

  • Liver enzymes at baseline and eight weeks: Checking alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase mitigates the liver-enzyme rises and spleen enlargement seen in rats at 150 mg/kg, which no human trial was powered to detect.

  • Prostate surveillance in men over 45: Annual prostate-specific antigen with a digital examination mitigates androgen-driven growth of prostate tissue, the risk implied by seminal vesicle enlargement in rodents.

  • Stopping on any androgen-excess signal: Treating scalp shedding, acne, aggression or an abrupt libido surge as grounds to stop mirrors the reported case, in which every feature resolved within one week of discontinuation.

Therapeutic Protocol

  • Standard regimen: Practitioners in Thailand use dried tuber powder at 100–250 mg once daily, the traditional range; the single randomised trial used 500 mg daily for four days, then 1000 mg daily, over three months.

  • Conventional alternative: Endocrinology practice for confirmed low testosterone uses testosterone replacement, targeting total testosterone of 400–700 ng/dL. It has replicated endpoint data this root lacks, and carries fertility suppression this root has not shown.

  • Integrative alternative: Integrative clinicians more often reach for ashwagandha, tongkat ali or fenugreek, each with pooled human hormone data. Neither approach is established as the default for a man with borderline testosterone and intact fertility.

  • Who popularised each approach: The Thai protocol traces to Wichai Cherdshewasart’s group at Chulalongkorn University; the Western supplement framing originates with online male-vitality retailers rather than any clinic or named practitioner.

  • Best time of day: Morning dosing on an empty stomach is conventional, aligning peak exposure with the natural early-morning testosterone peak and keeping any mild stimulant or vasodilatory effect away from sleep onset.

  • Half-life and dose splitting: The marker isoflavones clear with a half-life near seven to nine hours, so once-daily dosing keeps meaningful levels through the waking day; splitting into two smaller doses suits anyone reporting flushing or headache.

  • Genetic considerations: Equol producers and men carrying reduced-function UGT1A1 or high-activity SRD5A2 reach higher effective androgen exposure from the same capsule, so the lower end of the 100–250 mg range fits them better.

  • Sex-based differences: No dosing protocol exists for women. The androgenic actions shown in female rats, and the masculinising potential they imply, mean the traditional and trial protocols are male-only.

  • Age-related considerations: Men over 60 typically start at 100 mg daily, given slower clearance, higher baseline prostate volume and the greater consequence of any haematocrit rise at the older end of the target range.

  • Baseline biomarkers as a factor: Response is most plausible where total testosterone sits below 350 ng/dL with normal luteinising hormone; men already above 600 ng/dL have little headroom and face feedback suppression instead.

  • Pre-existing conditions: Diabetic and vascular erectile failure may still respond through the blood-flow route, which operated in diabetic rats; hormone-driven expectations are least reasonable in men with primary testicular failure.

Discontinuation & Cycling

  • Not a lifelong intervention: Traditional and trial use is time-limited, running weeks to three months rather than indefinitely. No study has followed continuous human use beyond twelve weeks, so open-ended dosing is entirely unstudied.

  • Withdrawal effects: None documented. In the one reported human case, raised dihydrotestosterone and the libido surge resolved within a week of stopping, with no rebound symptoms described.

  • Tapering: No taper protocol exists and none is indicated, since abrupt discontinuation in the published case produced clean reversal rather than any deficiency state or symptom rebound.

  • Cycling rationale: Eight weeks on and four weeks off is the common practical pattern. Its rationale is avoiding the prolonged high-dose exposure that lowered rodent testosterone at ninety days, not any demonstrated loss of effect.

  • Tolerance: No tolerance or escalating-dose requirement has been reported in humans. Users who feel the need to raise the dose are more plausibly encountering batch-to-batch potency variation than true tolerance.

  • Stopping alongside other agents: Where the root is one ingredient in a blended male-vitality product, stopping the whole product at once is simpler than isolating it, and makes any resolving symptom easier to attribute.

Sourcing and Quality

  • Species authentication comes first: Market Kwao Khruea drugs are commonly the wrong plant. Certificates naming Butea superba confirmed by DNA barcoding, or by restriction analysis of matK (a chloroplast gene used to identify plant species), are the only reliable proof of identity.

  • Part of plant matters: The tuberous root core, not stem or root bark, carries the studied constituents. The most active rodent extract came from dried root core; labels naming only aerial parts or unspecified herb are uninformative.

  • Provenance and season change potency: Constituent profiles vary markedly by Thai province and by harvest season, so the same nominal dose from two suppliers is not the same exposure. Batch-specific certificates of analysis are the practical safeguard.

  • Third-party testing for undeclared drugs: Because sexual-enhancement supplements are a recurring target for adulteration with erection drugs, independent screening for phosphodiesterase-5 inhibitors and their analogues matters more here than heavy-metal testing alone.

  • Standardisation is essentially absent: No accepted marker compound or potency standard exists for this root. Products standardised to total flavonoids or to named isoflavones such as daidzein at least allow comparison between batches.

  • Reputable supply routes: No brand can be named as verified: no third-party certification programme covers this root and no compounding pharmacy handles it. Thai Food and Drug Administration-registered manufacturers publishing ISO 17025-accredited batch certificates are the only identifiable option.

Practical Considerations

  • Time to effect: The randomised trial ran three months and reported improvement across that span; the case of androgen excess developed over a few weeks. A realistic assessment window is four to eight weeks.

  • Common pitfall — expecting a hormone result: No human study has measured testosterone after this root. Anyone tracking total testosterone as the success criterion is testing a claim the literature has never examined in people.

  • Common pitfall — attributing a blended product’s effect: The root is usually sold inside multi-ingredient stacks. Effects felt from such products cannot be attributed to Butea superba, and may reflect an undeclared drug rather than any botanical.

  • Common pitfall — dose escalation: Users who feel nothing often raise intake toward the gram-per-day range of the trial. That moves exposure toward the rodent doses associated with liver-enzyme rises and micronucleus formation.

  • Regulatory status: Sold as a dietary supplement in the United States under DSHEA (the 1994 law that lets supplements market without pre-approval) and as a registered traditional medicine in Thailand. It is not an approved medicine in the United States or Europe.

  • Cost and accessibility: Inexpensive and widely available online, typically well under 30 US dollars monthly. Neither it nor generic sildenafil is routinely reimbursed, so no insurer or health system has a financial incentive favouring either.

Interaction with Foundational Habits

  • Sleep: Indirect and potentially blunting. Sleep restriction is the single largest reversible suppressor of male testosterone, and no botanical offsets it. Morning dosing avoids any vasodilatory flushing or drive-related arousal near bedtime; the root has no sedative or stimulant action of its own.

  • Nutrition: Direct and potentiating. Isoflavone absorption depends on gut bacteria that convert daidzein, so fermented foods and adequate fibre plausibly raise exposure. Duplicate isoflavone sources such as soy protein isolate and red clover extract add to the same total load rather than acting independently.

  • Exercise: Indirect and potentiating. Resistance training and avoiding excessive endurance volume raise endogenous androgens far more reliably than this root. No blunting of training adaptation is reported, and no timing relative to workouts has been studied; morning dosing on training days is simply convenient.

  • Stress management: Indirect and potentiating. Chronic cortisol elevation suppresses the brain-to-testes hormone loop the root is claimed to act on, so unmanaged stress limits any ceiling. Rodent work suggests the extract itself has antidepressant-like activity, but no human mood or cortisol data exist.

Monitoring Protocol & Defining Success

Before starting, a baseline panel establishes whether there is any hormonal headroom to gain and any organ risk to watch. Blood is drawn fasting between 7 and 10 a.m., when testosterone peaks, and total testosterone is confirmed on two separate mornings before it is treated as real. The panel covers the androgen axis, the liver enzymes that rose in rodent toxicity work, blood count and prostate-specific antigen.

Ongoing monitoring follows the cycle rather than the calendar: the hormone and liver panel is repeated at 8 weeks, at the end of each subsequent cycle, and then every 6 to 12 months during continued use. Prostate-specific antigen is repeated annually in men over 45, and sooner if urinary symptoms appear. Success means measurable movement in free testosterone or erectile-function scores without a rise in haematocrit, liver enzymes or prostate-specific antigen.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Total testosterone 600–900 ng/dL The outcome the herb is taken for Conventional reference is wider at 264–916 ng/dL; drawn fasting 7–10 a.m. and confirmed on a second morning
Free testosterone 15–25 ng/dL The fraction actually available to tissue Calculated from total testosterone, SHBG (sex hormone-binding globulin, the carrier protein that holds testosterone inactive) and albumin; paired with total testosterone
Sex hormone-binding globulin 20–40 nmol/L Explains a total–free mismatch Isoflavones can raise it, so total testosterone may move without free testosterone following
Dihydrotestosterone Mid-range of 250–990 pg/mL The marker that rose in the only reported human case of androgen excess Best paired with total testosterone; scalp shedding or acne warrants an unscheduled check
Luteinising hormone 2–6 IU/L Falls when an outside androgen suppresses the brain-to-testes loop Drawn with testosterone in the same morning sample; a low value with low testosterone points to suppression
Follicle-stimulating hormone 1.5–8 IU/L Distinguishes testicular from pituitary causes of a low reading Same draw as luteinising hormone; relevant if fertility matters
Estradiol (sensitive assay) 20–30 pg/mL Detects estrogenic activity from the same extract The sensitive liquid-chromatography assay is required; standard immunoassays are unreliable in men
Alanine and aspartate aminotransferase Below 25 U/L each Liver enzymes that rose in rodents at high doses Conventional laboratories flag only above roughly 40 U/L; fasting draw, and intense exercise within 48 hours beforehand raises aspartate aminotransferase
Alkaline phosphatase 40–100 U/L Rose alongside aspartate aminotransferase in the 90-day rodent study Fasting draw; a rise with normal aminotransferases points to bone rather than liver
Haematocrit 40–48% Androgenic stimulation thickens blood and raises clotting risk Part of a complete blood count; above 52% is grounds to stop
Prostate-specific antigen Below 1.0 ng/mL under age 50; below 2.5 ng/mL thereafter Androgen-sensitive tissue growth is the main long-term concern Conventional cut-off is 4 ng/mL; ejaculation and cycling within 48 hours before the draw raise the reading, and the free-to-total ratio adds specificity

Qualitative markers worth tracking alongside the labs:

  • Morning erection frequency, recorded as mornings per week rather than an impression
  • Sexual desire, noting any abrupt surge, which in the published case signalled androgen excess rather than benefit
  • Energy and training drive, including session quality and willingness to start
  • Mood and irritability, given the antidepressant-like signal in animals and the aggression sometimes reported with androgen excess
  • Scalp shedding, acne and skin oiliness, the earliest visible signs of raised dihydrotestosterone
  • Sleep quality and night waking, to separate any true hormonal gain from a simple stimulant impression

Emerging Research

  • No registered trial of the plant exists: A ClinicalTrials.gov search on 2026-09-14 for Butea superba, by both general query and intervention field, returned zero records. The entire human evidence base remains two studies published in 2003 and 2010.

  • Comparator botanicals carry the registered evidence: NCT05347329, a completed three-arm randomised placebo-controlled trial of tongkat ali with maca in 197 men, measured erectile function and free and total testosterone. Its sponsor, Natural Wellness Egypt, markets the product tested.

  • Weak designs dominate the supplement registry: NCT05862519 enrolled 36 men in a single-group open-label study of four blended supplements using survey endpoints only. Designs of this type cannot separate ingredient effects and would not resolve the Butea superba question.

  • Constituent identification could strengthen the case: Sirichaiwetchakoon & Eumkeb, 2024 confirmed genistein, daidzein and biochanin A by mass spectrometry. Defining a marker compound would allow standardised dosing and make a properly powered human hormone trial feasible.

  • The androgen-axis direction could weaken it: Cherdshewasart et al., 2008 found falling rodent testosterone over 90 days while Sirichaiwetchakoon et al., 2021 found a rise over two weeks. A duration-controlled human study could show net suppression.

  • Authentication technology is maturing: Urumarudappa et al., 2022 built a reference DNA barcode library for Thai pharmacopoeial plants. Wider use would let buyers verify species identity and would quantify how often marketed Red Kwao Krua is something else.

  • Pharmacokinetics remain the largest gap: No human absorption, distribution or clearance study of the extract has been published. Until exposure is characterised, rodent doses cannot be translated and neither efficacy nor the rodent toxicity thresholds can be placed on a human scale.

Conclusion

Butea superba is the tuberous root of a Thai climbing legume, long taken by men as a vitality tonic and now sold worldwide as a testosterone booster. The claim and the evidence do not line up. No human study has ever measured testosterone after taking this root. What the human record contains is one small randomised trial reporting better erection questionnaire scores, and one later comparison whose apparent success collapsed when the product proved to be blended with an undeclared erection drug.

The plausible benefits are modest and indirect: some improvement in erectile function and in sexual drive, both graded low because the two human studies conflict. Everything hormonal rests on animals, where the direction reverses with duration — testosterone rose over two weeks and fell over three months.

The risks worth weighing are less about the plant than the product. Adulteration with prescription erection drugs is documented, species substitution in the market is common, and a single reported case shows the root can drive a real surge in male hormones that reverses on stopping.

The evidence base is small, produced largely by one Thai academic group and circulated by sellers with a direct financial stake in the result; no professional or advocacy body has taken a position on it either way. For a reader who tests, tracks and adjusts the dose, this is an inexpensive experiment in which the very thing it promises has never been measured, and in which the product itself is unusually variable.

Top - Benefits - Risks - Protocol